Key result
Metabolic inhibition test enables serologic diagnosis of group B Coxsackie virus in ~84% of cases.
Why the study?
Can a metabolic inhibition test effectively determine antibodies to group B Coxsackie viruses?
Population
Persons with suspected or previous group B Coxsackie virus infections
Design
Other
Authors
Loading...
May aid Coxsackie B serologic diagnosis; leaves open need for prospective clinical validation.
Can a metabolic inhibition test effectively determine antibodies to group B Coxsackie viruses?
A metabolic inhibition test can successfully provide serologic diagnosis for group B Coxsackie virus infections in up to 84% of cases.
Rogers et al. (1958) studied this question. The metabolic inhibition test for detecting antibodies to five group B Coxsackie virus serotypes enabled serologic diagnosis in up to 84% of cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: